Archive for the ‘Alzheimer’s’ Category

New Alzheimer’s Blood Test 94% Accurate

https://www.medscape.com/viewarticle/916372

New Alzheimer’s Blood Test 94% Accurate

Megan Brooks

August 02, 2019

A new blood test to detect brain changes emblematic of early Alzheimer’s disease (AD) has moved one step closer to reality and could be a “game changer” for the field.

Researchers found that measuring the ratio of β-amyloid (Aβ) 42 and Aβ40 in blood using a high-precision assay is 94% accurate in diagnosing brain amyloidosis, using amyloid PET or CSF phosphorylated (p-tau) 181/Aβ42 as reference standards.

“Right now we screen people for clinical trials with brain scans, which is time-consuming and expensive, and enrolling participants takes years,” senior investigator Randall J. Bateman, MD, professor of neurology, Washington University School of Medicine in St. Louis, said in a statement.

“But with a blood test, we could potentially screen thousands of people a month. That means we can more efficiently enroll participants in clinical trials, which will help us find treatments faster, and could have an enormous impact on the cost of the disease as well as the human suffering that goes with it,” he added.

The study was published online August 1 in Neurology.

Easy Screening Tool

Using an immunoprecipitation and liquid chromatography–mass spectrometry assay, the researchers measured Aβ42/Aβ40 in plasma and CSF samples from 158 older, mostly cognitively normal individuals (94% with Clinical Dementia Rate [CDR] = 0) that were collected within 18 months of an amyloid PET scan.

Plasma Aβ42/Aβ40 correlated highly with amyloid PET status (receiver operating characteristic area under the curve [AUC], 0.88; 95% confidence interval [CI], 0.82 – 0.93) and CSF p-tau181/Aβ42 (AUC, 0.85; 95% CI, 0.79 – 0.92), the researchers report.

The combination of plasma Aβ42/Aβ40, age, and apolipoprotein (APOE) ε4 status had “very high” correlation with amyloid PET (AUC, 0.94; 95% CI, 0.90 – 0.97), “suggesting that plasma Aβ42/Aβ40 may be used as a screening tool for those at risk of AD dementia,” the researchers write.

In addition, individuals with a positive plasma Aβ42/Aβ40 but negative amyloid PET scan have a 15-fold higher risk of converting to amyloid PET-positive (P = .01).

“The sensitivity of the plasma Aβ42/Aβ40 assay to amyloid PET-negative individuals who convert to amyloid PET-positive suggests that plasma Aβ42/Aβ40 becomes positive earlier than the established amyloid PET threshold used for this study,” Bateman and colleagues note in their report.

“Therefore, a positive plasma Aβ42/Aβ40 with a negative amyloid PET scan may represent early amyloidosis rather than a false-positive result in some individuals,” they add.

As reported by Medscape Medical News, the study builds on earlier work by the same researchers.

________________

For more: https://madisonarealymesupportgroup.com/2019/07/10/lyme-alzheimers-enbrel-new-potential-treatment/

https://madisonarealymesupportgroup.com/2019/04/09/the-diagnosis-is-alzheimers-but-thats-probably-not-the-only-problem/

https://madisonarealymesupportgroup.com/2019/03/09/researchers-identify-herpes-1-chlamydia-pneumoniae-several-types-of-spirochaete-as-major-causes-of-alzheimers/

https://madisonarealymesupportgroup.com/2017/01/18/a-bug-for-alzheimers/

https://madisonarealymesupportgroup.com/2016/06/09/alzheimers-byproduct-of-infection/

https://madisonarealymesupportgroup.com/2016/11/17/antibiotics-and-alzheimers/

https://madisonarealymesupportgroup.com/2016/06/03/borrelia-hiding-in-worms-causing-chronic-brain-diseases/

https://madisonarealymesupportgroup.com/2018/03/25/a-brief-history-of-neuroborreliosis-research-dementia-an-inside-look-at-two researchers/https://madisonarealymesupportgroup.com/2016/11/17/alzheimers-lyme

The Dementia Letters Project

https://samaritanministries.org/blog/member-spotlight-kathryne-fassbender-of-the-dementia-letters-project?

Kathryne Fassbender of the Dementia Letters Project

Brittany Klaus Jul 26, 2019

fassbender

Kathryn Fassbender

A passion for serving the elderly has led Kathryne Fassbender to start a dialogue about dementia to help both those living with the condition and their care partners.

At DementiaLettersProject.com, the Wisconsin resident and certified dementia communication specialist is creating the dialogue with input from care partners, family members, medical staff, and, most importantly, the individuals living with dementia.

The letters, she says, “can be (written) to dementia, to their future self who they fear might have dementia, or to a loved one with dementia. It can be expressing those fears, sharing their story of dementia, or sharing the gifts of dementia.”

Dementia is, according to CaringKind.com, the loss of cognitive functioning—thinking, remembering, and reasoning—and behavioral abilities to an extent that it interferes with a person’s daily life and activities.

“Dementia is an umbrella term that includes several different types of dementia with their own unique characteristics,” she says. “While dementia can take much away from one’s life, it does not take away their own experiences, joy, or spirit.”

Kathryne’s service to those affected by dementia started on a volunteer basis through middle-school service projects. She focused on aging.

“I was drawn into helping those with dementia first by finding that I connected well with individuals with dementia,” she says. By seeing the great misunderstanding her classmates had about the disease, she felt an even greater pull to work with those living with dementia.

Then in 2005 her grandmother was diagnosed with vascular dementia.

“Around that time not only was I experiencing dementia personally, but I was seeing how professionally it might evolve and become a professional vocation,” Kathryne says.

There is great healing through storytelling, and letter writing is a beautiful and easy form of storytelling.  Kathryne Fassbender

She earned her undergraduate degree in art therapy at Edgewood College in Wisconsin and interned at an adult day program that focused on dementia. From there she has gone on to work as a life-enrichment specialist and now leads dementia training workshops, works as a family consultant, speaks at conferences, and, in 2017, formed the Dementia Letters Project. Besides earning her CDCS last year, she also has earned a certificate in arts and health therapy.

Kathryne attributes the start of the Dementia Letters Project to “a couple of things colliding.”

She says she was beginning to discover people with dementia like Brian LeBlanc and Kate Swaffer who write blogs and are “calling out for people to recognize them and recognize their story and that their story is not what all medical professionals are telling us.”

“It’s not all doom and gloom, it’s not all memory loss and becoming medicalized,” Kathryne says.

She also noted family members and staff at a care community saying that they had fears about dementia but were afraid to share them and needed a platform where they could do that.

The Dementia Letters Project encourages others to share their story of dementia by writing letters for submission to DementiaLettersProject.com or for sharing within their family.

“These letters can be written to dementia itself, to the individual’s future self, or to a loved one with dementia,” she says. “It can express fears and joys about their personal story of dementia.”

Kathryne emphasizes that these letters are not all about fears, such as worry about when a loved one might the name of their children. It is also about those moments spent together that might not have happened without dementia. The goal of the Dementia Letters Project is to build a community that is “wealthy in hope and connection” for someone with dementia as well as friends, family, and care partners. The website also includes links to resources and Kathryne’s blog.

“My hope with the Dementia Letters Project is to allow those who may not want to be a visible voice via platforms like a blog, book, or speaking engagements to still be able to share their voice,” she says. “I also want families and community members to help us deepen the reality of dementia, to share their fears, their joys, their experiences. There is great healing through storytelling, and letter writing is a beautiful and easy form of storytelling.”

Kathryne says that dementia is more than what we’re reading in news articles or seeing on TV specials. It’s not only despondency; there is also joy, hope, and light—and conveying that to families and care communities has been Kathryne’s mission over the past two years.

“We need to be visionaries and servants of the Lord to individuals with dementia, despite our own fears and misunderstandings,” Kathryne says. “We have a duty to grow in knowledge about dementia and aging so that we can better minister to others.”

At the same time, Kathryne says we must not “medicalize” someone with dementia; we cannot forget to include their faith with the sudden checklist that appears with the diagnosis—making sure they eat, sleep, are dressed, and take prescribed medication. She encourages family members, friends, and care partners to ask themselves how they can make sure that their loved ones are still practicing their faith. Encouraging someone with dementia in their faith can be as simple as singing hymns with them or saying the Lord’s Prayer together—things that are ingrained in them, firmly rooted in their emotional memory.

To someone who is struggling with dementia, Kathryne says, “Your value never decreases in God’s eyes, and your ability to grow in faith never ceases.”

Kathryne spreads awareness and builds bridges by speaking at conferences. She realized there was a need for people who aren’t medical professionals but who are working with someone living with dementia to “enter the public speaking round.” She describes the medical community as being very “siloed,” especially when it comes to aging and dementia. Doctors and nurses will be in one silo and think they’re right, while academic researchers will be in their separate silo, and then those who take a more creative approach to dementia care will be in their silo.

“We need more bridges,” Kathryne says, “because we’re not really going to break the barrier of where we are right now with knowledge of dementia until we start communicating with each other and learn how to put our language into another person’s language, and then be able to share that with families. That’s where I am—trying to figure out that spot, that in-between spot, that can put medical research and creative aging language into layman’s terms.”

_________________

**Comment**

Please remember that both dementia and Alzheimer’s can be caused by Lyme/MSIDS. Deal with the infections and you can often gain cognitive ability back:  https://madisonarealymesupportgroup.com/2018/10/03/chronology-of-research-on-lyme-disease-dementia-alzheimers-parkinsons-autism/

https://madisonarealymesupportgroup.com/2019/06/22/dementia-from-illness/

https://madisonarealymesupportgroup.com/2019/04/27/breaking-news-definition-of-lyme-disease-dementia-has-improved/

https://madisonarealymesupportgroup.com/2018/03/25/a-brief-history-of-neuroborreliosis-research-dementia-an-inside-look-at-two-researchers/

https://madisonarealymesupportgroup.com/2017/06/10/the-coming-pandemic-of-lyme-dementia/

https://madisonarealymesupportgroup.com/2019/04/09/the-diagnosis-is-alzheimers-but-thats-probably-not-the-only-problem/

https://madisonarealymesupportgroup.com/2017/01/04/aluminum-alzheimers-ld/  Within this article, Dr. Marc Siegel explains on ‘Fox & Friends’ how Kris Kristofferson was diagnosed with Alzheimer’s but actually had Lyme Disease.  (Warning:  the news reporter propagates a myth that “One antibiotic,” prophylactically will cure LD if used early.)

Does Alzheimer’s Disease Stem From Infection? Scientists Debate & One Company Targets Gingivitis Bacterium to Slow Alzheimer’s Progression

https://www.medpagetoday.com/meetingcoverage/aaic/81065

Does Alzheimer’s Disease Stem From Infection?

Scientists debate, and one company targets gingivitis bacterium to slow Alzheimer’s progression

LOS ANGELES — Is there an infectious link to Alzheimer’s disease?

That’s a question of debate, and opinion was divided at the 2019 Alzheimer’s Association International Conference (AAIC) now underway here.

“Ideas in this area of research are still evolving; there is now growing evidence that microbes such as bacteria and viruses may play a role in degenerative brain diseases such as Alzheimer’s,” said Maria Carillo, PhD, chief science officer of the Alzheimer’s Association.

New research suggests infectious agents may be triggering immune reactions related to plaques and tangles and that loss of cognitive function in Alzheimer’s disease may stem from several different disease processes in the brain, not just one, she added.

A common virus coupled with a genetic factor — namely herpes simplexvirus 1 (HSV-1) and the APOE4 gene — can create a major risk for Alzheimer’s disease, noted Ruth Itzhaki, PhD, of the University of Manchester in England. The viral concept of Alzheimer’s proposes that HSV-1 in the brain of APOE4 carriers accounts a high percentage of Alzheimer’s cases. It postulates that HSV-1 travels to the brain earlier in life and establishes a latent infection that, when activated, “leads to viral damage in infected cells and viral-induced inflammation,” she said.

Recent studies have found an increased abundance of human herpesvirus6A (HHV-6A), HHV-7, HHV-6B, and HSV-1 in post-mortem Alzheimer’s disease brains, said Ben Readhead, MBBS, of Arizona State University in Tempe.

“These findings indicate that these species are capable of perturbing host cellular networks that are central to the pathogenesis of Alzheimer’s disease and offer testable hypotheses to guide further evaluation of the pathogen hypothesis of Alzheimer’s,” Readhead noted.

But associations seen in laboratory and epidemiological studies do not demonstrate causality, “and in fact, reverse causation must be considered more likely,” said Todd Golde, MD, PhD, of the University of Florida in Gainesville.

While neurodegeneration or other states “may very well enable slight reactivation of latent viruses present in many human brains” and there’s strong evidence that an additional hit from an infection can impair cognition, there’s no evidence for causality, he observed. “Trying to pin an infectious origin of Alzheimer’s disease on a virus or a bacteria may distract the field from more impactful research,” he said.

And open questions still need to be answered, said Michael Heneka, MD, PhD, of University Hospital Bonn in Germany. “The precise time point in the pathogenesis of Alzheimer’s at which bacteria may enter the brain needs to be determined, since these phenomena may present just late-stage events,” he said. “Furthermore, it remains elusive how bacteria would overcome the intrinsic innate immune defense of microglia that usually shield the brain from such invasion.”

One group looking for a causal link is testing whether targeting Porphyromonas gingivalis bacteria can slow or halt the progression of Alzheimer’s disease. In the GAIN trial, researchers from the biotech company Cortexyme are studying COR388 — an oral agent that inhibits gingipain proteases secreted by P. gingivalis, the culprit behind degenerative gum disease — in people with mild to moderate Alzheimer’s disease.

Earlier research identified the bacterium in brains and cerebrospinal fluid of people with Alzheimer’s disease, said Michael Detke, MD, PhD, Cortexyme’s chief medical officer, who reviewed the science behind the study at AAIC. Moreover, levels of gingipain proteases correlate with tau and ubiquitin pathology, Detke told MedPage Today.

Studies of wild type mice showed that oral infection with P. gingivalis invaded the brain and led to plaques, inflammation, and the loss of hippocampal neurons — effects which were blocked when the animals received COR388.

The drug was rapidly absorbed and well-tolerated in a phase I study of 24 older healthy volunteers. A smaller study of nine people with Alzheimer’s disease — six taking COR388 and three taking placebo – showed patients treated with the drug trended toward better memory scores and exhibited improvements in verbal skills, using more prepositions in their speech patterns over 28 days.

People taking COR388 also had reduced protein fragmentation and roughly 30% lower levels of inflammation, Detke said. The phase II/III GAIN trial in 570 Alzheimer’s patients in the U.S. and Europe is underway, with ADAS-Cog11 change at 48 weeks as the primary endpoint. Top-line results are expected late in 2021.

Itzhaki and Readhead reported no disclosures. Heneka reported relationships with IFM Therapeutics, Alector, Schering, Pfizer, Novartis, Roche, Abbvie, and Biogen, and is a co-inventor on patents and patent applications relating to Alzheimer’s diagnostics and therapeutics. Golde reported relationships with ProMIS Neuroscience, Eli Lilly, Novartis, Bristol Myers Squib, Abbvie, Lundbeck, Biogen, and Pfizer; he is a co-inventor on multiple patents and patent applications relating to Alzheimer’s therapeutics. Detke is an employee of Cortexyme.

________________

For more: https://madisonarealymesupportgroup.com/2019/04/09/the-diagnosis-is-alzheimers-but-thats-probably-not-the-only-problem/

https://madisonarealymesupportgroup.com/2019/03/09/researchers-identify-herpes-1-chlamydia-pneumoniae-several-types-of-spirochaete-as-major-causes-of-alzheimers/

https://madisonarealymesupportgroup.com/2017/01/18/a-bug-for-alzheimers/

https://madisonarealymesupportgroup.com/2016/06/09/alzheimers-byproduct-of-infection/

https://madisonarealymesupportgroup.com/2016/11/17/antibiotics-and-alzheimers/

https://madisonarealymesupportgroup.com/2016/06/03/borrelia-hiding-in-worms-causing-chronic-brain-diseases/

https://madisonarealymesupportgroup.com/2018/03/25/a-brief-history-of-neuroborreliosis-research-dementia-an-inside-look-at-two researchers/https://madisonarealymesupportgroup.com/2016/11/17/alzheimers-lyme

Lyme, Alzheimer’s, Enbrel – New Potential Treatment

http://lymemd.blogspot.com/2019/06/lyme-alzheimers-enbrel-new-potential.html

Thursday, June 6, 2019

By Dr. Jaller

Lyme, Alzheimer’s, Enbrel — New Potential Treatment

iu

I have learned that most people want a simple sound bite answer or conclusion. The edges of medicine always operate in the grey and nuanced.

It has long been dogma in Lyme circles that immune suppressing drugs, e.g. Enbrel are very dangerous and should not be used.  The same is true with prednisone.

I have patients who get the occasional injection by their rheumatologist; joint pain gets better and they are no worse for the wear.

The drug is used for psoriasis amongst other many other conditions. The drug has serious side effects: its use should not be taken lightly.

A study suppressed by Pfizer, brought to light by the Washington Post, was based on insurance company data considering outcomes of  hundreds of thousands of patients and found those taking Enbrel had a 64% decrease in the incidence of Alzheimer’s disease. 

Enbrel impairs the function of TNF alpha, a master cytokine responsible for trafficking immune cells.

Pfizer did not make the disclosure because: a generic version will be  available.  A shiny new, me-too drug promoted heavily by pharm reps costing obscene amounts of money will take its place. Doctors will be given shiny data, along with lunch, proving equivalency? with the old drug.

The myth that generics are poor (dangerous) and lack quality control may be resurrected.

Watch out for first year generic prices: cute trick. For the first year a single company is given a monopoly and only required to reduce the price by 20%.  “See, the generic is almost as cheap as the brand,” the rep will inform a doctor. This is a bad pro big-pharma rule passed by Congress decades ago I’m sure) by the way. Cheap is a relative term.

The pharmaceutical giant, Pizer has excuses, reasons why it withheld the data, for example, they  claimed the data is wrong because of biological plausibility: the molecule is too large to cross the blood brain barrier.

Really? I care if the molecule gets into the brain; maybe it’s an advantage.  The brain has its own immune system which needs to be tweaked lightly. Ask anyone who has had a brain Herxheimer reaction knows. The Cytokine storm which may make you crazy results from peripheral cytokine reactions/overproduction primarily.  And there is no data the molecule cannot get into the brain. Cytokines get in the brain.

Alzheimer’s is in part motivated by inflammation. Other major factors are: production of amyloid beta protein (AB) (plaques and tangles), genetic factors and multiple external factors.

It is thought that AB protein is a naturally occurring antibiotic which responds to inflammation. Discussed elsewhere. Lyme resides in the brain along with many  bacteria, viruses, protozoans. It is true that spirochetes have been reported to aid in the transportation of AB into the brain.  Infection (or colonization) may be omnipresent and therefore not the whole story — or the most critical piece.

The vast majority of my patients present with cognitive complaints. Many or most Lyme patients, at one time or another fit the criteria for a disorder call MCI, minimal cognitive impairment. The mainstream medical community considers this a pre-Alzheimer’s condition, often.

What’s a Lyme patient to do?

First off, if symptoms completely resolve with usual therapy do nothing.

If you are a patient who has had very aggressive therapy, e.g. months of IV antibiotics and cognitive symptoms persist, look up MCI and consider the following:

Get an AB PET. The tests measures metabolic activity in the brain and the presence of early AB protein deposition. IF the test is positive you are at very high risk for developing Alzheimer’s.

Prednisone and Enbrel have largely been seen as dangerous because patients are misdiagnosed and not also treated for Lyme. Enbrel is likely tolerably safe, in many cases, considering benefit to risk ratio.

A lot of money has been spent searching for an Alzheimer’s cure. To no avail. Nothing very promising in the literature.

I for one am very angry with Pfizer. I suppose it is typical behavior in the industry. We still need big pharma. Don’t throw out the baby with bathwater. Hold them accountable. But, do not  conclude big pharma is corrupt therefore all drugs developed through the system are fruit of a poisoned tree and are therefore inherently untrustworthy and dangerous — in addition to being immorally overpriced.

It’s a bad syllogism. Drug companies are a very necessary evil.

Getting back to Enbrel.  Is this a silver bullet?.  More comment, biostatistics and analysis are required as well as prospective RCT medical studies. Since the drug will be generic soon big pharma will not finance the research. Fortunately, Alzheimer’s, a burgeoning epidemic as our population ages, is well funded through private sources.

Ideal prospective studies, which will likely be done make observations moving forward starting with a baseline current population. The process is slow.

Retrospective, population studies, primarily manipulation of data already there will not take long. These studies are never as good as prospective studies but perhaps good enough.

If you want my  bottom line: don’t run out and get Enbrel– YET.

I am not endorsing the use of the drug for any medical condition, including Alzheimer’s. This site is for informational purposes only. Medical care can only be delivered by a certified medical practioner who properly evaluates your particular issues. Please don’t diagnose or treat yourself

http://www.drjaller.com Dr. Jaller’s practice is in Maryland
__________________________
Regarding immune suppressants, many LLMD’s use them IF the patient is also on antimicrobial therapy at the same time. This tandem usage will protect the patient from a worsening infection(s), be it Lyme or any of the coinfections or even a latent infection.
Talk with your doctor about all treatments.

Response From Dr. Paul Auwaerter Regarding the IDSA Grant (Part 2)

https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/24788664?

Response from Dr. Paul Auwaerter regarding the IDSA grant (Part 2)

JUL 5, 2019 — 

Please see today’s letter to the TBDWG…….

———- Original Message ———-
From: CARL TUTTLE <runagain@comcast.net>
To: tickbornedisease@hhs.gov, chris.smith@mail.house.gov
Cc: (98 Undisclosed recipients)
Date: July 5, 2019 at 9:07 AM
Subject: NEW: Response from Dr. Paul Auwaerter regarding the IDSA grant to search for an infectious cause of Alzheimer’s disease.

July 5, 2019

The IDSA Foundation
1300 Wilson Boulevard Suite 300
Arlington, VA 22209
Attn:  Paul Auwaerter, vice chair of the IDSA Foundation

Dear Dr. Auwaerter,

Lyme disease is recognized as the fastest growing vector-borne infectious disease in the United States with an estimate of over 300,000 new cases yearly. [i] It is imperative that at least one (or more) of those $100,000 IDSA Foundation grants is earmarked for research related to Borrelia infections and possible connection to Alzheimer’s disease.

Rheumatic fever as you know is a consequence of untreated strep throat leading to irreversible heart disease. We have evidence that untreated Lyme is just as destructive as Dr. Neil Spector’s untreated Lyme infection required a heart transplant.[ii]  Kris Kristofferson’s untreated Lyme led to a misdiagnosis of Alzheimer’s disease [iii] and Dr. Vincent M. Tedone has identified Lyme in his daughter’s neurodegenerative ALS diagnosis. [iv]

Personal Health; When Lyme invades the brain and spinal system.

By  JANE E. BRODY FEB. 15, 1995

https://www.nytimes.com/1995/02/15/us/personal-health-when-lyme-invades-the-brain-and-spinal-system.html

——————-

Focusing on the acute stage of Lyme disease after early treatment misses the horribly disabled who have gone months, years or decades before diagnosis and it’s time to recognize this fault in the science.

Subjective symptoms after treatment of early Lyme disease.
https://www.ncbi.nlm.nih.gov/pubmed/20102996
Gary Wormser, New York Medical College Jan 2010

It is common knowledge that Dr. Allen Steere has had a career long fixation on the swollen arthritic knee presentation of Lyme disease.

“Charting the scope of Lyme disease”
Marisa Venegas, New York Times 1988 Accession number 30957138

Quote from Dr. Raymond Dattwyler:

“This disease can involve virtually every organ system of the body, Dr. Dattwyler said. It makes sense to look at this as a whole-body disease, rather than narrowly. In syphilis, which is a similar spirochetal illness in some ways, there is also arthritis. If I concentrated on that aspect of syphilis, it would be ludicrous….”

And then there is this paper from Dr. Robert Bransfield…..

Aggressiveness, violence, homicidality, homicide, and Lyme disease  Oct 2017
https://www.dovepress.com/aggressiveness-violence-homicidality-homicide-and-lyme-disease-peer-reviewed-fulltext-article-NDT

_________________________

Dr. Auwaerter,

It is imperative that research continues in the area of Borrelia infections and possible connection to Alzheimer’s disease and I must insist that funding be restricted from the researchers who are identified as defendants in the racketeering lawsuit as these individuals clearly have a conflict of interest.

The following list of additional references was recently brought to my attention:

Alzheimer’s disease, dementia, Parkinson’s disease, brain atrophy caused by spirochetes and other pathogens of infectious diseases

http://www.erlebnishaft.de/alzheimerspirochaetosis.pdf

Respectfully submitted,

Carl Tuttle

Lyme Endemic Hudson, NH

Cc: Tick-Borne Disease Working Group

References:

[i] Data and Surveillance

https://www.cdc.gov/lyme/datasurveillance/index.html
[ii] Doctor Hopes His Medical Journey Inspires Others

https://www.dukehealth.org/blog/doctor-hopes-his-medical-journey-inspires-others
[iii] “A Slow Slipping Away”— Kris Kristofferson’s Long-Undiagnosed Battle with Lyme Disease

https://www.huffpost.com/entry/a-slow-slipping-away-kris-kristoffersons-long_b_577c047be4b00a3ae4ce6609
[iv] A Revolutionary Idea: Bacteria Causes Neurodegenerative Conditions

https://www.winningthefight.org/bacteria–nerve-disease.html

_______________________________________

On July 3, 2019 at 8:12 AM Paul Auwaerter <pauwaert@jhmi.edu> wrote:

Dear Mr. Tuttle,

The grants for research are evaluated by an independent scientific review board. I do not sit on this board, and I cannot speak for them. The IDSA Foundation encourages applications, and we do not exclude any pathogen.  I expect the grant awards to be highly competitive.

Sincerely,

Paul G. Auwaerter, MD

Vice Chair, IDSA Foundation
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland USA

Assistant: Stephanie Knight

Email: sknigh22@jhmi.edu

T: 443-287-4800

F: 410-502-7029

Personal Health; When Lyme invades the brain and spinal system.
Meanwhile, within weeks of entering the body, the spirochete, a bacterium that resembles the organism that causes syphilis, can…

Pathology Lecture On Lyme Disease in Human Brains – Microbiologist Tom Grier

https://nextdoor.com/events/2954936/?init_source=facebook_share&fbclid=IwAR05xoPFYU-8fD_KV343BtkSFZgaLF42x1pwX_pLh3qkOTW6YILtiqLJN-I  (Sign up here)

Pathology Lecture Lyme disease in Human Brains

Tue, May 21, 6:00 PM – 8:00 PM

Event details

Tuesday May 21st, 6 PM Superior Library all are welcome FREE! This is a lecture on human brain research looking for the Lyme bacteria in Alzheimer’s brains. Several local cases will be discussed. (This is not a Lyme prevention lecture.) The family of bacteria that causes Lyme disease has been known for 100+ years to enter the human brain. Yet no tax dollars have ever been spent to study the effects of Lyme disease in the human brain. We have images of both Borrelia miyamotoi and Borrelia burgdorferi forming biofilms inside amyloid plaques in Alzheimer’s brains.

Please bring your friends for coffee and cookies and a medical discussion on cutting edge research. Lyme disease is not the easily diagnosed and easily treated disease that we have been told about, it is found inside human cells including neurons, and behind the blood brain barrier where blood tests cannot detect it, and the new species of Borrelia are not detected by any tests. For more photos email me at tomgrier@gmail.com Not recommended for young kids to attend. Nothing is being sold or promoted accept new research. Tom Grier

__________________

**Comment**

If you are able to attend this lecture, I highly recommend it.  Tom has done amazing work and has uncovered many important aspects of this disease(s) that mainstream medicine is frankly ignoring.

For more:  https://madisonarealymesupportgroup.com/2019/04/28/lyme-disease-lecture-notes-microbiologist-tom-grier/

https://madisonarealymesupportgroup.com/2016/12/19/microbiologist-tom-grier/

https://madisonarealymesupportgroup.com/2016/08/09/dr-paul-duray-research-fellowship-foundation-some-great-research-being-done-on-lyme-disease/

 

 

Seven Conditions Lyme Disease Gets Misdiagnosed As

https://www.bustle.com/p/7-conditions-lyme-disease-gets-misdiagnosed-as-17041598

7 Conditions Lyme Disease Gets Misdiagnosed As

WHYFRAME/Shutterstock

Lyme disease is a notoriously difficult condition to test for, and many doctors aren’t knowledgeable about it, which leads lots of Lyme patients to get misdiagnosed. The misdiagnoses of Lyme range from physical illnesses to psychological ones and often occur because Lyme can affect any organ system in the body in a multitude of ways, leading it to be labeled the “great imitator.”

What further compounds the confusion is that many people don’t notice contracting Lyme. “Infectious nymphal ticks are tiny — poppy seed sized — and tick bites can often go unnoticed. Most people never know they were bitten,” Sunjya K. Schweig, MD, scientific advisor to Bay Area Lyme Foundation, tells Bustle.

“The current ‘gold standard’ diagnostic for Lyme disease misses up to 60 percent of cases of early stage Lyme disease. If caught early, most cases of Lyme disease can be treated, but it is commonly misdiagnosed due to lack of awareness and unreliable diagnostic tests. If not treated promptly, Lyme may progress to a debilitating stage.”

Late-stage Lyme symptoms include paralysis, arthritis, neurological problems, headaches, cognitive impairment, memory problems, hearing and vision problems, inflammation of the brain (meningitis), and inflammation of the heart (carditis or pericarditis), Dr. Schweig says. But when people present with these symptoms, doctors don’t usually think to test for Lyme.

“It is important to recognize that Lyme disease is the most common vector-borne disease in the US, and the diagnosis should always be part of an appropriate differential diagnosis,” Dr. Schweig says. “There are about 329,000 new cases of Lyme disease each year.”

Here are some conditions that Lyme is commonly mistaken for, according to experts.

1. Fibromyalgia

Mladen Zivkovic/Shutterstock

“The symptoms reported by patients diagnosed with fibromyalgia are almost identical to those associated with chronic Lyme disease,” Bill Rawls, MD, an integrative health expert on Lyme disease and other chronic illnesses, tells Bustle. These include joint pain, stiffness, fatigue, and brain fog. It’s unknown what exactly causes fibromyalgia, but Dr. Rawls believes it’s likely that it is usually caused by Lyme and/or other microbes.

2. Chronic Fatigue Syndrome

Rawpixel/Shutterstock
Similar to fibromyalgia, chronic fatigue syndrome doesn’t have a known cause, and there’s a strong possibility that it is typically caused by Lyme and/or other microbes, according to Dr. Rawls. Fatigue is a hallmark sign of Lyme, and chronic fatigue syndrome is also associated with other Lyme symptoms, like impaired memory and joint pain.

3. Multiple Sclerosis

Iryna Inshyna/Shutterstock

Multiple Sclerosis is a central nervous system disease that affects myelin, the substance surrounding nerve fibers, causing symptoms like numbness, weakness, poor coordination, and vision problems. It has been linked to a variety of microbes including Borrelia burgdorferi, the bacteria known to cause Lyme, as well as chlamydia and the Espstein-Barr virus, Dr. Rawls says.

4. Arthritis

Rocketclips Inc/Shutterstock

Lyme can cause pain, swelling, stiffness, and loss of function in the joints — similar symptoms to osteoarthritis and rheumatoid arthritis, Timothy J. Sellati, Ph.D., the Global Lyme Alliance’s chief scientific officer, tells Bustle. You can sometimes distinguish these conditions because Lyme is more likely to affect the large joints of the legs and occasionally the wrists, while other types of arthritis are more often in the hands, wrists, shoulders, knees, and feet. But the distinction isn’t always that clear-cut, so they’re often confused.

5. Amyotrophic Lateral Sclerosis

Dusan Petkovic/Shutterstock
Amyotrophic lateral sclerosis (ALS) is a condition involving degeneration of nerve cells in the brain and spinal cord, leading muscles to atrophy. Its symptoms include muscle twitching and cramps and weakness in the hands, legs, feet, or ankles, Dr. Sellati says, which can also be symptoms of neurological Lyme disease. In fact, research has found that people with ALS are five times as likely to carry Borrelia Burgdorferi as the rest of the population.

6. ADHD

RK-studio/Shutterstock

One common byproduct of Lyme’s effect on the brain is impaired concentration and memory, which can be confused with disorders like ADHD, Daniel Cameron, MD, MPH, an internist and epidemiologist who specializes in treating Lyme, tells Bustle. The brain fog and sleep disturbances that many people with Lyme experience compounds these issues.

In older people, these symptoms can sometimes be diagnosed as Alzheimer’s disease — and in fact, some research has linked Alzheimer’s to Borrelia burgdorferi. Research has also suggested that lipopeptides, the fatty acids created by Lyme bacteria, could interfere with communication between neurons, which may explain the memory and concentration difficulties.

7. Mental Illness

Photographee.eu/Shutterstock

People with chronic illnesses, especially women, often face the misconception that the root of their symptoms is psychological. This is especially true for Lyme. Lyme can cause a range of mental health symptoms including anxiety, depression, and rage, leading many Lyme patients to be diagnosed with mental illness, Dr. Cameron says.

It’s difficult to tell whether a psychiatric illness is caused by Lyme, but a sudden onset of psychiatric symptoms with no apparent cause, especially in conjunction with a tick bite or other Lyme symptoms, could point toward it.

Dr. Rawls believes anyone diagnosed with the most common Lyme misdiagnoses should look into the possibility that their condition is being caused by Lyme, co-infections, or similar microbes. But treatment doesn’t mean taking a round of antibiotics, which are often ineffective for chronic infections. Most people with Lyme have many different microbes that are very antibiotic-resistant, he explains, so the key is not to go after them in isolation but to strengthen the gut and immune system in order to keep them at bay.

“Restoration of normal immune system functions with natural therapy and suppression of stealth microbes with herbal therapy is often highly effective for restoring a normal state of health in affected individuals,” he says. “This approach is safe, nontoxic, and not dependent on a diagnosis. It should be the foundation for therapy for every one of these chronic illnesses.”

____________________

**Comment**

This idea that antibiotics don’t work is a bit premature.  The studies have numerous flaws and have only been on a certain subset of patients.  All I know is I’d more than likely be dead without them (my husband as well), with many other patients stating the same. Whenever you read someone’s opinion on Lyme treatment, always take into account what they are selling.  Dr. Rawls is selling herbs, plain and simple.  It’s a business for him.  Just keep that in mind. While a patient himself, he has a vested interest in getting you to buy his products.

Recently, an article came out stating there’s an “untreatable” form of Lyme.  Read my rebuttal here:  https://madisonarealymesupportgroup.com/2019/04/29/is-the-sky-truly-going-to-fall-for-patients-with-the-untreatable-form-of-lyme-disease/

This IS treatable.  It very well may not be curable, but then this is nothing new.  The chicken pox virus isn’t truly curable in that it lies around in our spine – same with EBV.  It’s only when our bodies become weak and out of balance that these things rear their little, ugly heads.  So immune regulation IS important, but never, ever buy the line that antibiotics don’t work for this.  (Of course there’s always exceptions to each and every rule).

Many advocates believe the Newsweek article is part of an orchestrated ploy to sell an upcoming Lyme vaccine.  Authorities refuse to do transmission studies, drug effectiveness studies (on chronic patients), and so many other important issues needing resolution, but they keep coming back to the vaccine issue like buzzards drawn to dead bodies for the simple reason they smell a lot of money and many through the years have patents on the vaccine itself as well as Lyme test kits and other metabolomics: ConflictReport  (Patents start on page 80)  Conflicts of interest abound in every aspect of this.

As to the Lyme vaccine, please, please, do your reading:  https://madisonarealymesupportgroup.com/2018/07/22/why-we-care-so-strongly-about-a-potential-lyme-vaccine/

https://madisonarealymesupportgroup.com/2018/07/01/lyme-vaccine-fail-safety-ignored/

https://madisonarealymesupportgroup.com/2018/01/28/the-secret-x-files-the-untold-history-of-the-lymerix-vaccine/

Nothing about anything Lyme/MSIDS related has a magic bullet.  If someone says there is a magic bullet, they are selling something, pure and simple.